Go Pro
→ Your book is inside (From Profits Run) (Ad)tc pixel Free BBOT Stock Alerts

BridgeBio Oncology Therapeutics (BBOT) Competitors

BridgeBio Oncology Therapeutics logo
$8.31 -0.10 (-1.19%)
Closing price 04:00 PM Eastern
Extended Trading
$8.29 -0.02 (-0.24%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

BBOT vs. UNIT, INFQ, NTST, GNL, and SILA

Should you buy BridgeBio Oncology Therapeutics stock or one of its competitors? MarketBeat compares BridgeBio Oncology Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Oncology Therapeutics include Uniti Group (UNIT), Infleqtion (INFQ), NETSTREIT (NTST), Global Net Lease (GNL), and Sila Realty Trust (SILA). These companies are all part of the "trading" industry.

How does BridgeBio Oncology Therapeutics compare to Uniti Group?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Uniti Group (NASDAQ:UNIT) are both trading companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

BridgeBio Oncology Therapeutics currently has a consensus target price of $24.80, indicating a potential upside of 198.44%. Uniti Group has a consensus target price of $11.14, indicating a potential upside of 1.45%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Uniti Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Uniti Group
0 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.33

BridgeBio Oncology Therapeutics has a beta of 0.39, meaning that its stock price is 61% less volatile than the broader market. Comparatively, Uniti Group has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

In the previous week, BridgeBio Oncology Therapeutics had 3 more articles in the media than Uniti Group. MarketBeat recorded 6 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Uniti Group. Uniti Group's average media sentiment score of 0.90 beat BridgeBio Oncology Therapeutics' score of 0.54 indicating that Uniti Group is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Uniti Group
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. Comparatively, 87.5% of Uniti Group shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Uniti Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Uniti Group has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Uniti Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.05N/A
Uniti Group$2.23B1.19$1.30B$3.353.28

Uniti Group has a net margin of 39.61% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A N/A N/A
Uniti Group 39.61%N/A -3.44%

Summary

Uniti Group beats BridgeBio Oncology Therapeutics on 9 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Infleqtion?

Infleqtion (NYSE:INFQ) and BridgeBio Oncology Therapeutics (NASDAQ:BBOT) are both small-cap financial services companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

In the previous week, BridgeBio Oncology Therapeutics had 1 more articles in the media than Infleqtion. MarketBeat recorded 6 mentions for BridgeBio Oncology Therapeutics and 5 mentions for Infleqtion. BridgeBio Oncology Therapeutics' average media sentiment score of 0.54 beat Infleqtion's score of 0.04 indicating that BridgeBio Oncology Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Infleqtion
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Infleqtion currently has a consensus target price of $21.00, suggesting a potential upside of 132.69%. BridgeBio Oncology Therapeutics has a consensus target price of $24.80, suggesting a potential upside of 198.44%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Infleqtion.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Infleqtion
1 Sell rating(s)
1 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.71
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75

BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Infleqtion's return on equity.

Company Net Margins Return on Equity Return on Assets
InfleqtionN/A -60.34% -15.09%
BridgeBio Oncology Therapeutics N/A N/A N/A

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Infleqtion is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InfleqtionN/AN/A-$66.93M-$0.09N/A
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.05N/A

Summary

BridgeBio Oncology Therapeutics beats Infleqtion on 10 of the 13 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to NETSTREIT?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and NETSTREIT (NYSE:NTST) are both trading companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

In the previous week, NETSTREIT had 1 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 7 mentions for NETSTREIT and 6 mentions for BridgeBio Oncology Therapeutics. NETSTREIT's average media sentiment score of 0.91 beat BridgeBio Oncology Therapeutics' score of 0.54 indicating that NETSTREIT is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NETSTREIT
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BridgeBio Oncology Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, NETSTREIT has a beta of 0.82, suggesting that its share price is 18% less volatile than the broader market.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by insiders. Comparatively, 0.7% of NETSTREIT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NETSTREIT has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than NETSTREIT, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.05N/A
NETSTREIT$192.67M11.18$6.90M$0.13170.38

NETSTREIT has a net margin of 5.29% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. NETSTREIT's return on equity of 0.78% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A N/A N/A
NETSTREIT 5.29%0.78%0.43%

BridgeBio Oncology Therapeutics currently has a consensus target price of $24.80, suggesting a potential upside of 198.44%. NETSTREIT has a consensus target price of $22.45, suggesting a potential upside of 1.34%. Given BridgeBio Oncology Therapeutics' higher probable upside, equities research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than NETSTREIT.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
NETSTREIT
0 Sell rating(s)
3 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.81

Summary

NETSTREIT beats BridgeBio Oncology Therapeutics on 12 of the 15 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Global Net Lease?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Global Net Lease (NYSE:GNL) are both small-cap trading companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, media sentiment, dividends, risk and analyst recommendations.

54.9% of BridgeBio Oncology Therapeutics shares are held by institutional investors. Comparatively, 61.2% of Global Net Lease shares are held by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are held by company insiders. Comparatively, 0.6% of Global Net Lease shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Global Net Lease had 1 more articles in the media than BridgeBio Oncology Therapeutics. MarketBeat recorded 7 mentions for Global Net Lease and 6 mentions for BridgeBio Oncology Therapeutics. Global Net Lease's average media sentiment score of 0.75 beat BridgeBio Oncology Therapeutics' score of 0.54 indicating that Global Net Lease is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Global Net Lease
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BridgeBio Oncology Therapeutics has higher earnings, but lower revenue than Global Net Lease. Global Net Lease is trading at a lower price-to-earnings ratio than BridgeBio Oncology Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.05N/A
Global Net Lease$495.29M4.04-$225.46M-$0.40N/A

BridgeBio Oncology Therapeutics presently has a consensus price target of $24.80, suggesting a potential upside of 198.44%. Global Net Lease has a consensus price target of $10.33, suggesting a potential upside of 9.52%. Given BridgeBio Oncology Therapeutics' higher possible upside, analysts plainly believe BridgeBio Oncology Therapeutics is more favorable than Global Net Lease.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Global Net Lease
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.86

BridgeBio Oncology Therapeutics has a net margin of 0.00% compared to Global Net Lease's net margin of -8.72%. BridgeBio Oncology Therapeutics' return on equity of 0.00% beat Global Net Lease's return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A N/A N/A
Global Net Lease -8.72%-2.90%-1.07%

BridgeBio Oncology Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Global Net Lease has a beta of 1.02, indicating that its share price is 2% more volatile than the broader market.

Summary

BridgeBio Oncology Therapeutics and Global Net Lease tied by winning 8 of the 16 factors compared between the two stocks.

How does BridgeBio Oncology Therapeutics compare to Sila Realty Trust?

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) and Sila Realty Trust (NYSE:SILA) are both small-cap trading companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

54.9% of BridgeBio Oncology Therapeutics shares are owned by institutional investors. 24.4% of BridgeBio Oncology Therapeutics shares are owned by insiders. Comparatively, 0.8% of Sila Realty Trust shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, BridgeBio Oncology Therapeutics had 3 more articles in the media than Sila Realty Trust. MarketBeat recorded 6 mentions for BridgeBio Oncology Therapeutics and 3 mentions for Sila Realty Trust. Sila Realty Trust's average media sentiment score of 1.20 beat BridgeBio Oncology Therapeutics' score of 0.54 indicating that Sila Realty Trust is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BridgeBio Oncology Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sila Realty Trust
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

BridgeBio Oncology Therapeutics currently has a consensus target price of $24.80, indicating a potential upside of 198.44%. Sila Realty Trust has a consensus target price of $29.50, indicating a potential downside of 2.83%. Given BridgeBio Oncology Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe BridgeBio Oncology Therapeutics is more favorable than Sila Realty Trust.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BridgeBio Oncology Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.75
Sila Realty Trust
0 Sell rating(s)
6 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.14

BridgeBio Oncology Therapeutics has a beta of 0.39, suggesting that its stock price is 61% less volatile than the broader market. Comparatively, Sila Realty Trust has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

Sila Realty Trust has higher revenue and earnings than BridgeBio Oncology Therapeutics. BridgeBio Oncology Therapeutics is trading at a lower price-to-earnings ratio than Sila Realty Trust, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BridgeBio Oncology TherapeuticsN/AN/A-$134.04M-$2.05N/A
Sila Realty Trust$201.95M8.31$33.12M$0.6745.31

Sila Realty Trust has a net margin of 18.64% compared to BridgeBio Oncology Therapeutics' net margin of 0.00%. Sila Realty Trust's return on equity of 2.81% beat BridgeBio Oncology Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
BridgeBio Oncology TherapeuticsN/A N/A N/A
Sila Realty Trust 18.64%2.81%1.81%

Summary

Sila Realty Trust beats BridgeBio Oncology Therapeutics on 9 of the 15 factors compared between the two stocks.

Get BridgeBio Oncology Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for BBOT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBOT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BBOT vs. The Competition

Export
MetricBridgeBio Oncology TherapeuticsInvestment Offices IndustryFinancial SectorNASDAQ Exchange
Market Cap$665.69M$292.22M$6.20B$12.45B
Dividend YieldN/AN/A5.24%9.44%
P/E Ratio-4.052.1130.0624.25
Price / SalesN/A18,697.761,776.1387.39
Price / CashN/A136.03114.2060.03
Price / Book1.62353.416.536.23
Net Income-$134.04M-$66.54M$1.13B$331.94M
7 Day Performance-8.58%-0.82%0.04%-1.92%
1 Month Performance7.50%-0.68%0.05%-0.96%
1 Year PerformanceN/A2.58%15.52%18.25%

BridgeBio Oncology Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BBOT
BridgeBio Oncology Therapeutics
3.064 of 5 stars		$8.31
-1.2%		$24.80
+198.4%		N/A$665.69MN/AN/AN/A
UNIT
Uniti Group
1.7129 of 5 stars		$10.83
-2.5%		$11.14
+2.9%		+147.0%$2.63B$2.23B3.238,632
INFQ
Infleqtion
2.661 of 5 stars		$11.18
-4.8%		$21.00
+87.8%		N/A$2.44BN/AN/A2
NTST
NETSTREIT
2.7664 of 5 stars		$21.47
-0.9%		$22.45
+4.6%		+22.0%$2.09B$195.01M165.1330
GNL
Global Net Lease
1.9963 of 5 stars		$9.07
+0.7%		$10.40
+14.7%		+22.2%$1.92B$495.29MN/A1

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:BBOT) was last updated on 7/16/2026 by MarketBeat.com Staff.
From Our Partners
The only metrics you should watch as a day trader.
Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...
The TradingPub | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
VWAV: Is This the Next Defense Breakout?
VisionWave Holdings (NASDAQ: VWAV) is developing a full-stack defense technology platform integrating AI, RF s...
Equiscreen | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel